298 related articles for article (PubMed ID: 31092048)
1. Emerging angiogenesis inhibitors for non-small cell lung cancer.
Malapelle U; Rossi A
Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
[No Abstract] [Full Text] [Related]
2. Examining the safety profile of angiogenesis inhibitors: implications for clinical practice.
Reck M
Target Oncol; 2010 Dec; 5(4):257-67. PubMed ID: 20842461
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
Scagliotti G; Govindan R
Oncologist; 2010; 15(5):436-46. PubMed ID: 20427383
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
[TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
7. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
9. [Targeted therapies in the treatment of non-small cell lung cancer].
De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
[TBL] [Abstract][Full Text] [Related]
11. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
13. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
14. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
Marco S; Tomasini P; Greillier L; Barlesi F
Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Bronte G; Passiglia F; Galvano A; Russo A
Expert Opin Biol Ther; 2016; 16(1):1-5. PubMed ID: 26235195
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenesis and lung cancer].
Pérol M; Arpin D
Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
[TBL] [Abstract][Full Text] [Related]
18. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
Pilotto S; Novello S; Peretti U; Kinspergher S; Ciuffreda L; Milella M; Carbognin L; Vavalà T; Ferrara R; Caccese M; Tortora G; Bria E
Expert Opin Investig Drugs; 2015; 24(9):1143-61. PubMed ID: 26065529
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.
Crinò L; Metro G
Eur Respir Rev; 2014 Mar; 23(131):79-91. PubMed ID: 24591665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
